[Translation] A single-center, blinded, placebo- and positive vaccine-controlled phase I clinical trial of the safety, tolerability, and preliminary exploration of immunogenicity of quadrivalent influenza virus split vaccine (MDCK cells) in healthy people aged 6 months and above
主要目的:
四价流感病毒裂解疫苗(MDCK细胞)在6月龄及以上健康人群中接种的安全性。
次要目的:
四价流感病毒裂解疫苗(MDCK细胞)在6月龄及以上健康人群中接种的免疫原性。
探索性目的:
探索3~8岁人群以2种免疫程序接种四价流感病毒裂解疫苗(MDCK细胞)的免疫原性。
[Translation] Primary objective:
Safety of quadrivalent influenza virus split vaccine (MDCK cells) in healthy people aged 6 months and above.
Secondary objective:
Immunogenicity of quadrivalent influenza virus split vaccine (MDCK cells) in healthy people aged 6 months and above.
Exploratory objective:
Explore the immunogenicity of quadrivalent influenza virus split vaccine (MDCK cells) in 2 immunization schedules in people aged 3 to 8 years.